AAPL326.59-7.15 (-2.14%) ▼|ABBV253.38-1.11 (-0.44%) ▼|ABT101.66+0.98 (+0.97%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|AAPL326.59-7.15 (-2.14%) ▼|ABBV253.38-1.11 (-0.44%) ▼|ABT101.66+0.98 (+0.97%) ▲|ACN144.73+1.16 (+0.81%) ▲|ADBE234.74-2.51 (-1.06%) ▼|AMAT525.70-3.96 (-0.75%) ▼|AMD503.57+7.81 (+1.58%) ▲|AMGN364.17-2.12 (-0.58%) ▼|AMT167.06-3.00 (-1.76%) ▼|AMZN249.99+2.76 (+1.12%) ▲|AVGO378.16+7.34 (+1.98%) ▲|AXP351.93-3.42 (-0.96%) ▼|BA209.48-4.55 (-2.13%) ▼|BAC60.42-0.85 (-1.39%) ▼|BKNG179.45-2.23 (-1.23%) ▼|BLK1,054.11-18.09 (-1.69%) ▼|BMY60.16-0.58 (-0.95%) ▼|BNY156.93-0.20 (-0.13%) ▼|BRK-B491.25+0.34 (+0.07%) ▲|C128.72-0.64 (-0.49%) ▼|CAT864.30-14.35 (-1.63%) ▼|CL91.93-0.52 (-0.56%) ▼|CMCSA23.78-0.01 (-0.04%) ▼|COF206.77-1.26 (-0.61%) ▼|COP115.68+0.97 (+0.85%) ▲|COST935.80-5.07 (-0.54%) ▼|CRM173.79+3.02 (+1.77%) ▲|CSCO110.70-1.24 (-1.11%) ▼|CVS107.61+0.14 (+0.13%) ▲|CVX189.71+2.33 (+1.24%) ▲|DE586.00-11.24 (-1.88%) ▼|DHR201.11-2.72 (-1.33%) ▼|DIS96.41-1.26 (-1.29%) ▼|DUK125.85+0.84 (+0.67%) ▲|EMR136.58-2.96 (-2.12%) ▼|FDX306.22-6.76 (-2.16%) ▼|GD370.60+2.02 (+0.55%) ▲|GE341.30-7.53 (-2.16%) ▼|GEV1,079.18+21.34 (+2.02%) ▲|GILD133.21-1.07 (-0.80%) ▼|GM75.80-0.27 (-0.35%) ▼|GOOG351.37+5.25 (+1.52%) ▲|GOOGL351.99+5.22 (+1.51%) ▲|GS1,055.03-10.19 (-0.96%) ▼|HD333.04-5.83 (-1.72%) ▼|HON226.18+1.16 (+0.52%) ▲|IBM213.00+0.33 (+0.16%) ▲|INTC97.06+2.02 (+2.13%) ▲|INTU293.82+2.73 (+0.94%) ▲|ISRG353.17+7.75 (+2.24%) ▲|JNJ248.82-4.22 (-1.67%) ▼|JPM338.87-2.23 (-0.65%) ▼|KO82.12+0.56 (+0.69%) ▲|LIN512.05-1.17 (-0.23%) ▼|LLY1,146.90-32.21 (-2.73%) ▼|LMT509.54+0.77 (+0.15%) ▲|LOW204.71-4.02 (-1.93%) ▼|LRCX306.76-6.54 (-2.09%) ▼|MA547.44+3.84 (+0.71%) ▲|MCD267.64-0.07 (-0.03%) ▼|MDLZ60.27-0.73 (-1.20%) ▼|MDT83.29+0.09 (+0.11%) ▲|META645.85-0.16 (-0.02%) ▼|MMM159.11-0.73 (-0.46%) ▼|MO74.66+0.45 (+0.61%) ▲|MRK124.40-3.10 (-2.43%) ▼|MS210.94-4.56 (-2.12%) ▼|MSFT402.29+8.47 (+2.15%) ▲|MU865.46+16.51 (+1.94%) ▲|NEE88.00-0.80 (-0.90%) ▼|NFLX67.60-1.35 (-1.96%) ▼|NKE43.47-0.29 (-0.66%) ▼|NOW104.70+1.46 (+1.41%) ▲|NVDA203.28+0.47 (+0.23%) ▲|ORCL121.38-5.03 (-3.98%) ▼|PEP135.46-1.66 (-1.21%) ▼|PFE24.75-0.30 (-1.20%) ▼|PG149.13-0.85 (-0.57%) ▼|PLTR134.85+2.47 (+1.87%) ▲|PM192.72-0.26 (-0.13%) ▼|QCOM170.32-1.46 (-0.85%) ▼|RTX194.44+0.93 (+0.48%) ▲|SBUX104.81-0.68 (-0.64%) ▼|SCHW102.54+0.98 (+0.96%) ▲|SO94.46-0.84 (-0.88%) ▼|SPG228.19-0.51 (-0.22%) ▼|T21.95+0.14 (+0.64%) ▲|TMO526.23-6.25 (-1.17%) ▼|TMUS195.64+3.21 (+1.67%) ▲|TSLA369.57-11.27 (-2.96%) ▼|TXN284.07+0.05 (+0.02%) ▲|UBER72.17-0.29 (-0.40%) ▼|UNH421.55-4.54 (-1.07%) ▼|UNP296.25-5.50 (-1.82%) ▼|UPS113.15-4.57 (-3.88%) ▼|USB63.14+0.00 (+0.00%) ▲|V360.57+2.01 (+0.56%) ▲|VZ43.50-0.09 (-0.21%) ▼|WFC86.33-1.18 (-1.35%) ▼|WMT112.20-2.04 (-1.79%) ▼|XOM148.36+1.00 (+0.68%) ▲|
28.3 C
New York
Monday, July 20, 2026

Tag: chest pain

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

JellyFil Discloses 2026 Botanical Ingredient Sourcing, cGMP Manufacturing Standards, Caffeine Content, and Consumer Safety Considerations for Its Premium Gummy Dietary Supplement

JellyFil discloses 2026 gummy supplement ingredient origins, cGMP manufacturing standards, caffeine content, and drug interaction guidance.

The Best Cold Plunge Tubs of 2026 [Expert Picks]

Home-wellness resource ranks nine cold plunge brands across ten best-in-class categories, naming Sun Home Best Overall and Best Portable, with Plunge, Nordic Wave, Tru...

Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment

Cardiawave Announces First Routine Treatments Performed with Valvosoft® Following CE Mark Approval and Accelerates Its Deployment

Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products

Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce HONG KONG, June 15, 2026 /PRNewswire/ -- Kingworld Medicines Group Limited ("Kingworld...

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

HeroMD 4-MAX scam or legit? Compounded 4-in-1 sublingual ED formula with 10-min onset and 36-hr window reviewed.

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

Ally Medical ER Is Coming to Magnolia

Ally Medical Emergency Room is opening in Magnolia, TX near FM 1488 in 2027 — 24/7 care, board-certified physicians, no wait times for Montgomery County.

Emmaus Life Sciences Reports Quarterly Financial Results

TORRANCE, Calif., Aug. 14, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell...

Heartflow, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of $19 per share, which includes 2,500,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were offered by Heartflow. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, were approximately $364.2 million. Heartflow’s common stock began trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol “HTFL.”

Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering

MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public offering of 16,666,667 shares of its common stock at a public offering price of $19.00 per share. All of the shares of common stock are being offered by Heartflow. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, are expected to be approximately $316.7 million. In addition, Heartflow has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol "HTFL.” The closing of the offering is expected to occur on August 11, 2025, subject to the satisfaction of customary closing conditions.

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer’s disease

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsChest pain